Please login to the form below

Not currently logged in
Email:
Password:

AZ agrees generics deal with Torrent

AstraZeneca is to enter into an agreement with Torrent Pharmaceuticals to purchase the licenses to a portfolio of generic medicines

AstraZeneca (AZ) has announced it is to enter into an agreement with Indian based drug makers Torrent Pharmaceuticals to purchase the licenses to a portfolio of generic medicines.

The deal will see the anglo-Swedish pharmaceutical giants obtain from Torrent the licenses and market authorisations for 18 products in nine countries, with AZ looking to 'capitalise' on the increasing prospects for pharmaceutical companies in emerging markets, including India.

In a statement, AZ claimed that emerging markets are "forecast to contribute around 70 per cent of pharmaceutical industry growth in the next five years, and branded generics represent approximately 50 per cent by value in these emerging markets."

As part of the deal, for which no financial details were disclosed, AZ will also gain the flexibility to add further products and new countries for which the company sees expansion opportunities.

Torrent, who currently produce and supply its products into more than 50 countries, will continue to manufacture the medicines.

Tony Zook, head of AstraZeneca's global commercial organisation, said: "In markets where consumers and physicians have a strong preference for trusted brands, we believe AstraZeneca's long-standing reputation for quality is a sustainable competitive advantage. Working in partnership with Torrent will extend the range of branded medicines we can offer to patients in emerging markets, where we see continuing opportunities for our business to grow."

11th March 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OPEN Access Consulting

OPEN Access Consulting is a specialist market access agency within the OPEN Health Group. As value communications experts we specialise...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics